PMID- 35528781
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220510
IS  - 2666-1683 (Electronic)
IS  - 2666-1691 (Print)
IS  - 2666-1683 (Linking)
VI  - 39
DP  - 2022 May
TI  - Safety and Feasibility of Soractelite Transperineal Focal Laser Ablation for 
      Prostate Cancer and Short-term Quality of Life Analysis from a Multicenter Pilot 
      Study.
PG  - 48-54
LID - 10.1016/j.euros.2022.02.012 [doi]
AB  - BACKGROUND: Soractelite transperineal focal laser ablation (TPLA) for the 
      treatment of localized prostate cancer (PCa) using the Echolaser(R) system is a 
      novel minimally invasive technique that has the potential to induce tissue 
      ablation, while reducing treatment-related morbidity, when compared with 
      robot-assisted radical prostatectomy (RARP) and radiotherapy. OBJECTIVE: To 
      determine the short-term safety and feasibility of single or multifiber TPLA, its 
      functional outcomes, and quality of life (QoL). DESIGN SETTING AND PARTICIPANTS: 
      TPLA was performed in 12 patients, consecutively assigned to four treatment 
      regimens, with localized PCa who were scheduled for RARP ("ablate and resect 
      design"). The treatment regimens were as follows: (1) a single fiber at 3 W, (2) 
      two fibers at 5 mm distance at 3 W, (3) two fibers at 10 mm distance at 3 W, and 
      (4) a single fiber at 5 W. TPLA was scheduled 4 wk prior to RARP. INTERVENTION: 
      TPLA using the Echolaser(R) system under local anesthesia at the outpatient clinic. 
      OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Safety and feasibility were 
      determined by the assessment of device-related peri- and postoperative adverse 
      events (AEs), and length of hospital stay. Functional outcomes and QoL were 
      measured using validated questionnaires. Feasibility of RARP was assessed by a 
      questionnaire for the urologist. RESULTS AND LIMITATIONS: Patients were dismissed 
      after a median (interquartile range) hospital admission of 3.25 (1.25) h. No 
      device-related AEs occurred. AEs that occurred were mostly related to lower 
      urinary tract symptoms and were mild (grade 1-2). Most AEs resolved within 1 wk. 
      A QoL analysis showed no significant differences for all treatment regimens. 
      Functional outcomes remained unchanged, except for erectile function after 1 wk, 
      which returned to baseline after 4 wk. TPLA treatment did not compromise RARP, 
      based on the questionnaires. CONCLUSIONS: TPLA for the treatment of PCa at the 
      outpatient clinic appears to be safe and feasible with good short-term QoL and 
      functional outcomes; oncological results are awaited. PATIENT SUMMARY: Focal 
      treatment of localized prostate cancer can safely be performed in a daycare 
      setting using a new technique, based on laser ablation, without compromising 
      quality of life.
CI  - (c) 2022 The Author(s).
FAU - van Riel, Luigi A M J G
AU  - van Riel LAMJG
AD  - Urology, Amsterdam University Medical Centres: Amsterdam Universitair Medische 
      Centra, Amsterdam, the Netherlands.
FAU - van Kollenburg, Rob A A
AU  - van Kollenburg RAA
AD  - Urology, Amsterdam University Medical Centres: Amsterdam Universitair Medische 
      Centra, Amsterdam, the Netherlands.
FAU - Vis, Andre N
AU  - Vis AN
AD  - Urology, Amsterdam University Medical Centres: Amsterdam Universitair Medische 
      Centra, Amsterdam, the Netherlands.
FAU - van Leeuwen, Pim J
AU  - van Leeuwen PJ
AD  - Netherlands Cancer Institute: Antoni van Leeuwenhoek Nederlands Kanker Instituut, 
      Amsterdam, the Netherlands.
FAU - de Reijke, Theo M
AU  - de Reijke TM
AD  - Urology, Amsterdam University Medical Centres: Amsterdam Universitair Medische 
      Centra, Amsterdam, the Netherlands.
FAU - de Bruin, Daniel M
AU  - de Bruin DM
AD  - Urology and Biomedical Engineering & Physics, Amsterdam University Medical 
      Centres: Amsterdam Universitair Medische Centra, Amsterdam, the Netherlands.
FAU - Oddens, Jorg R
AU  - Oddens JR
AD  - Urology, Amsterdam University Medical Centres: Amsterdam Universitair Medische 
      Centra, Amsterdam, the Netherlands.
LA  - eng
PT  - Journal Article
DEP - 20220402
PL  - Netherlands
TA  - Eur Urol Open Sci
JT  - European urology open science
JID - 101771568
PMC - PMC9068724
OTO - NOTNLM
OT  - Focal therapy
OT  - Laser ablation
OT  - Minimally invasive therapy
OT  - Prostatic neoplasm
EDAT- 2022/05/10 06:00
MHDA- 2022/05/10 06:01
PMCR- 2022/04/02
CRDT- 2022/05/09 04:00
PHST- 2022/02/27 00:00 [accepted]
PHST- 2022/05/09 04:00 [entrez]
PHST- 2022/05/10 06:00 [pubmed]
PHST- 2022/05/10 06:01 [medline]
PHST- 2022/04/02 00:00 [pmc-release]
AID - S2666-1683(22)00059-3 [pii]
AID - 10.1016/j.euros.2022.02.012 [doi]
PST - epublish
SO  - Eur Urol Open Sci. 2022 Apr 2;39:48-54. doi: 10.1016/j.euros.2022.02.012. 
      eCollection 2022 May.